RT Journal Article
T1 Inflammation, a common mechanism in frailty and COVID-19, and stem cells as a therapeutic approach
A1 Becerra, José
A1 Duran, Ivan
K1 Aging
K1 COVID-19
K1 Frailty
K1 Immunomodulation
K1 Inflammation
K1 Mesenchymal stem cell
K1 MSC
K1 Regeneration
K1 Stem cell exhaustion
K1 Envejecimiento
K1 Fragilidad
K1 Inmunomodulación
K1 Inflamación
K1 Células madre mesenquimatosas
K1 Regeneración
AB As our life expectancy increases, specific medical conditions appear, and new challenges are met in terms of global health. Frailty has become a medical and scientific concept to define pathologies where inflammation, depressed immune system, cellular senescence, and molecular aging converge. But more importantly, frailty is the ultimate cause of death that limits our life span and deteriorates health in an increasing proportion of the world population. The difficulty of tackling this problem is the combination of factors that influence frailty appearance, such as stem cells exhaustion, inflammation, loss of regeneration capability, and impaired immunomodulation. To date, multiple research fields have found mechanisms participating in this health condition, but to make progress, science will need to investigate frailty with an interdisciplinary approach. This article summarizes the current efforts to understand frailty from their processes mediated by inflammation, aging, and stem cells to provide a new perspective that unifies the efforts in producing advanced therapies against medical conditions in the context of frailty. We believe this approach against frailty is particularly relevant to COVID-19, since people in a state of frailty die more frequently due to the hyperinflammatory process associated with this infection.
PB AlphaMed Press, Inc.
SN 2157-6564
YR 2021
FD 2021-08-03
LK http://hdl.handle.net/10668/3457
UL http://hdl.handle.net/10668/3457
LA en
NO Becerra J, Duran I. Inflammation, a common mechanism in frailty and COVID-19, and stem cells as a therapeutic approach. Stem Cells Transl Med. 2021 Nov;10(11):1482-1490.
DS RISalud
RD Apr 5, 2025